NNZ-2566, a Novel Analog of (1–3) IGF-1, as a Potential Therapeutic Agent for Fragile X Syndrome

  title={NNZ-2566, a Novel Analog of (1–3) IGF-1, as a Potential Therapeutic Agent for Fragile X Syndrome},
  author={Robert M. J. Deacon and Larry Glass and Michael F. Snape and Michael J. Hurley and F. J. Altimiras and Rodolfo R. Biekofsky and Patricia Cogram},
  journal={NeuroMolecular Medicine},
AbstractFragile X syndrome (FXS) is the most common form of inherited intellectual disability. Previous studies have implicated mGlu5 in the pathogenesis of the disease, and many agents that target the underlying pathophysiology of FXS have focused on mGluR5 modulation. In the present work, a novel pharmacological approach for FXS is investigated. NNZ-2566, a synthetic analog of a naturally occurring neurotrophic peptide derived from insulin-like growth factor-1 (IGF-1), was administered to… 

The therapeutic potential of insulin-like growth factor-1 in central nervous system disorders

Lymphocytic Extracellular Signal Regulated Kinase Dysregulation in Autism Spectrum Disorder.

An Update on Psychopharmacological Treatment of Autism Spectrum Disorder

Current psychopharmacological treatment in ASD including those used to address common comorbidities of the condition and upcoming new targeted approaches in autism management are reviewed.

Rett Syndrome and Fragile X Syndrome: Different Etiology With Common Molecular Dysfunctions

The mechanisms of synaptic function and plasticity altered in RTT and FXS are discussed, and most of the common targets of MeCP2 and FMRP are involved in brain activity.

Criss‐crossing autism spectrum disorder and adult neurogenesis

The interconnections between the molecular pathways related to AN and ASD are approached and existing therapeutic approaches targeting such pathways both in preclinical and clinical studies are discussed.

Effects of the sigma-1 receptor agonist blarcamesine in a murine model of fragile X syndrome: neurobehavioral phenotypes and receptor occupancy

The present findings support the viability of S1R as a therapeutic target inFXS, and the clinical potential of blarcamesine in FXS and other neurodevelopmental disorders.



Minireview: Expanding the Mind: Insulin-Like Growth Factor I and Brain Development

IGF1R signaling stimulates the proliferation, survival, and differentiation of each of the major neural lineages, neurons, oligodendrocytes, and astro- cytes, as well as possibly influencing neural stem cells.

Identification of Gly-Pro-Glu (GPE), the aminoterminal tripeptide of insulin-like growth factor 1 which is truncated in brain, as a novel neuroactive peptide.

Fragile X syndrome. Molecular and clinical insights and treatment issues.

  • R. Hagerman
  • Medicine, Psychology
    The Western journal of medicine
  • 1997
Advances have also occurred in the treatment of the fragile X syndrome, and psychopharmacologic and educational interventions are reviewed here.

AFQ056, a new mGluR5 antagonist for treatment of fragile X syndrome

Hippocampal lesions, species-typical behaviours and anxiety in mice

IGF‐1 derived small neuropeptides and analogues: a novel strategy for the development of pharmaceuticals for neurological conditions

The research suggests that small neuropeptides have advantages over growth factors in the treatment of brain injury, and that modified neuropePTides designed to overcome the limitations of their endogenous counterparts represent a novel strategy of pharmaceutical discovery for neurological disorders.

The Successive Alleys Test of Anxiety in Mice and Rats

  • R. Deacon
  • Biology, Psychology
    Journal of visualized experiments : JoVE
  • 2013
A modification of the plus-maze design that not only eliminates the central area but also incorporates elements from other anxiety tests, such as the light-dark box and emergence tests, which provides a useful confirmation of plus- maze results which would be useful when, for example, only a single example of a mutant mouse was available, as, for instance, in ENU-based mutagenesis programs.

Regulation of Dendritic Morphogenesis by Ras–PI3K–Akt–mTOR and Ras–MAPK Signaling Pathways

The data underscore the central role of a spatiotemporally regulated key cell survival and growth pathway on trophic regulation of the coordinated development of dendrite size and shape.